Advertisement

Drugs

pp 1–8 | Cite as

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease

  • Matt ShirleyEmail author
Adis Drug Evaluation

Abstract

Amikacin liposome inhalation suspension (ALIS; Arikayce®) [formerly known as liposomal amikacin for inhalation, or LAI] is a liposomal formulation of the aminoglycoside antibacterial drug amikacin. The ALIS formulation, administered via inhalation following nebulization, is designed to facilitate targeted and localized drug delivery to the lungs while minimizing systemic exposure. Based on the prespecified primary endpoint analysis of the ongoing phase III CONVERT trial, ALIS has been approved in the USA for use as part of a combination antibacterial drug regimen against Mycobacterium avium complex (MAC) lung disease that is treatment refractory (i.e. an active infection present despite ≥ 6 consecutive months of a multidrug regimen) in adult patients who have limited or no alternative treatment options. In the CONVERT trial, once-daily ALIS as an add-on to guidelines-based therapy (GBT) significantly increased the odds of achieving sputum culture conversion by month 6 compared with GBT alone in patients with treatment-refractory MAC lung disease. The addition of ALIS to GBT was associated with an increased risk of respiratory adverse events compared with GBT alone; however, serious adverse events were experienced by a similar proportion of patients in the two treatment groups. In conclusion, although current evidence for efficacy is limited to microbiological outcomes (with clinical benefit yet to be established), available data suggest that ALIS is a useful option for the treatment of patients with MAC lung disease who have not responded to conventional therapy and for whom there are limited or no alternative treatment options available.

Notes

Acknowledgments

During the peer review process, the manufacturer of ALIS was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.CrossRefPubMedGoogle Scholar
  2. 2.
    Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014;6(3):210–20.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Park HY, Jeong B-H, Chon HR, et al. Lung function decline according to clinical course in nontuberculous mycobacterial lung disease. Chest. 2016;150(6):1222–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011;105(11):1718–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018;18(1):206.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Marras TK, Vinnard C, Zhang Q, et al. Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population. Respir Med. 2018;145:80–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Winthrop K, Adjemian J, Mirsaeidi M, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries, 2008–2015 [abstract 780 and poster]. In: ID week. 2018.Google Scholar
  8. 8.
    Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538–44.CrossRefPubMedGoogle Scholar
  11. 11.
    Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549–55.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61(4):859–68.CrossRefPubMedGoogle Scholar
  13. 13.
    Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559–69.CrossRefGoogle Scholar
  14. 14.
    US FDA. Arikayce® (amikacin liposome inhalation suspension): US prescribing information. 2018. http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207356s000lbl.pdf. Accessed 19 Feb 2019.
  15. 15.
    National Institutes of Health—US National Library of Medicine. Amikacin sulfate injection: US prescribing information. 2018. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ec3129b-c53b-4bdb-913d-a2d0060fa140. Accessed 19 Feb 2019.
  16. 16.
    Brown-Elliott BA, Iakhiaeva E, Griffith DE, et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol. 2013;51(10):3389–94.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25(3):545–82.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zhang J, Leifer F, Rose S, et al. Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol. 2018;9:915.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Rose SJ, Neville ME, Gupta R, et al. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS One. 2014;9(9):e108703.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Malinin V, Neville M, Eagle G, et al. Pulmonary deposition and elimination of liposomal amikacin for inhalation and effect on macrophage function after administration in rats. Antimicrob Agents Chemother. 2016;60(11):6540–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Weers J, Metzheiser B, Taylor G, et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv. 2009;22(2):131–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Insmed Ltd. Amikacin liposome inhalation suspension: Antimicrobial Drugs Advisory Committee briefing materials. 2018. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM615723.pdf. Accessed 19 Feb 2019.
  23. 23.
    Olivier KN, Maass-Moreno R, Whatley M, et al. Airway deposition and retention of liposomal amikacin for inhalation in patients with pulmonary nontuberculous mycobacterial disease [abstract A3732 and poster]. Am J Respir Crit Care Med. 2016;193:A3732.Google Scholar
  24. 24.
    Brown-Elliott BA, Eagle G, Wallace Jr RJ, et al. Amikacin liposome inhalation suspension (ALIS) add-on therapy for refractory Mycobacterium avium complex (MAC) lung disease: effect of in vitro amikacin susceptibility on sputum culture conversion [abstract 805 and poster]. In: ID week. 2018.Google Scholar
  25. 25.
    Winthrop KL, Eagle G, Morimoto K, et al. Extension study of Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory lung disease caused by Mycobacterium avium complex (MAC): interim analysis [abstract and poster]. Chest. 2018;154(4 Suppl):182A–3A.CrossRefGoogle Scholar
  26. 26.
    Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195(6):814–23.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kwak N, Park J, Kim E, et al. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis. 2017;65(7):1077–84.CrossRefPubMedGoogle Scholar
  28. 28.
    Wallace RJ Jr, Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146(2):276–82.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Weers J. Inhaled antimicrobial therapy—barriers to effective treatment. Adv Drug Deliv Rev. 2015;85:24–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Awuh JA, Flo TH. Molecular basis of mycobacterial survival in macrophages. Cell Mol Life Sci. 2017;74(9):1625–48.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations